IN THE HIGH COURT OF JUSTICE
BUSINESS AND PROPERTY COURTS OF ENGLAND AND WALES
INTELLECTUAL PROPERTY LIST (ChD)
PATENTS COURT

Claim No. HP-2020-000042

**BETWEEN:** 

**SANDOZ LIMITED** 

**Claimant** 

-and-

## BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY (a company incorporated under the laws of Ireland)

**Defendant** 

Claim No. HP-2021-000003

AND BETWEEN:

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (a company incorporated under the laws of Israel)

**Claimant** 

-and-

BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY (a company incorporated under the laws of Ireland)

**Defendant** 

\_\_\_\_\_

## ANNEX A TO THE STATEMENT OF GROUNDS

\_\_\_\_\_

- 1. By this application in the event that the validity of claim 7 of the Patent (as unamended) is not upheld BMS seek to introduce two new claims namely:
  - 7A. A compound of claim 1 or 2 that is a factor Xa inhibitor for use in treating a thromboembolic disorder.
  - 7B. A compound of claim 1 or 2 <u>that is an effective factor Xa inhibitor</u> for use in treating a thromboembolic disorder.